1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Alumis Looks To Stand Out From The TYK2 Crowd With Psoriasis Data

Company Announces Series C Raise

 
• By Alaric DeArment

The privately held company announced data at AAD showing high PASI 75 rates in both a randomized Phase II trial and an open-label extension study.

• Source: Shutterstock

Following on Bristol Myers Squibb Company’s US Food and Drug Administration approval of the first-in-class TYK2 inhibitor Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis in late 2022, numerous other firms are lining up to develop the next TYK2-targeting agent for autoimmune diseases. Alumis, Inc., with positive Phase II data, thinks it might have a best-in-class molecule in ESK-001.

Alumis presented data from the 228-patient Phase II STRIDE trial of ESK-001 at the American Academy of Dermatology annual meeting on 9 March for ESK-001, which it describes as a...

Key Takeaways

  • Alumis announced positive Phase II results for ESK-001, its TYK2 inhibitor candidate, in moderate-to-severe plaque psoriasis.

  • The company plans to start Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.